Efficacy and Safety of Mepolizumab in Eosinophilic COPD: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | Synapse
April 28, 2026
Efficacy and Safety of Mepolizumab in Eosinophilic COPD: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Key Points
To evaluate the efficacy and safety of mepolizumab in treating eosinophilic COPD.
Systematic review and meta-analysis of randomized controlled trials
Focused on the effects of mepolizumab on exacerbation rates and safety
Included data on symptom-free periods and adverse events
Mepolizumab reduced time to first moderate or severe exacerbation significantly (exact rates not provided)
Prolonged symptom-free periods were noted in treated individuals
No increase in adverse events reported compared to control
Abstract
Mepolizumab reduces the time to first moderate or severe exacerbation and prolongs symptom-free periods in patients with eosinophilic COPD, without increasing the risk of AEs.